Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by McBullishon Aug 21, 2024 12:30pm
209 Views
Post# 36190059

RE:Where's the real news?

RE:Where's the real news? Update from call:

Will file for pre-BTD in Q3 IF they get the clinical data in time.
IF accepted, they have 60 days for BTD approval (possibly Q4)

3 more candidates joining the clinical trial, bringing it to 75. Target 10 candidates more by EOY brinbging it to 85 total.

One comment that was concerning to me was regarding competition. During Rogers presentation on TLT's cash burn rate, he compared TLT to another company that has similiar clinical results and recently been granted BTD. Roger was stating that company had a 500M burn rate, but didnt go into detail on the competitions drug/treatment that was approved for BTD.

Does anyone know what this is? It sounds as if its large pharma and its results are comparable to TLT's. Considering its already been granted BTD, it will make it market way before us and they clearly dont have a funding/cashflow issue.
<< Previous
Bullboard Posts
Next >>